Immune Therapeutics, Inc. Announces First Sales & Shipment of Lodonal; Receives Trademark and Patent Approval From Federal Republic of Nigeria

ORLANDO, Fla., Feb. 20, 2018 (GLOBE NEWSWIRE) via OTC PR WIRE Immune Therapeutics, Inc. (OTCQB:IMUN) ( Immune “IMUN” or the Company ), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal” and IRT-101 “MENK”) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs,  today announced the company has shipped its initial order of Lodonal to AHAR Pharma in Nigeria.  In addition, IMUN has received both trademark and patent approval from the Federal
http://bit.ly/2sKodCi